Basic Information
Pemetrexed Accord
Regulatory Information
EMEA/H/C/004072
January 18, 2016
November 19, 2015
13
February 12, 2025
Company Information
Spain
Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona
ACCORD HEALTHCARE SL
Drug Classification
Active Substances Detail
pemetrexed disodium hemipentahydrate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication **Malignant pleural mesothelioma** Pemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. **Non-small cell lung cancer** Pemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Pemetrexed Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pemetrexed Accord. For practical information about using Pemetrexed Accord, patients should read the package leaflet or contact their doctor or pharmacist.